Company Overview of Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for helping patients and improving patient care. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, skin, and infectious diseases and conditions. The company also provides patient assistance programs to manage diseases and conditions. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1...
One Health Plaza
East Hanover, NJ 07936-1080
Founded in 1968
Key Executives for Novartis Pharmaceuticals Corporation
President, US Country Head and President of Novartis Corporation
Chief Financial and Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2015.
Novartis Pharmaceuticals Corporation Key Developments
Novartis Pharmaceuticals Corporation Finalizes Settlement Agreement Resolving Civil Suit Filed by US Attorney's Office for Southern District of New York
Nov 20 15
Novartis Pharmaceuticals Corporation has finalized the settlement in principle, which was previously disclosed, to resolve a civil suit filed by the U.S. Attorney's Office for the Southern District of New York related to NPC's interactions with specialty pharmacies for the drugs Exjade and Myfortic. NPC is still in the process of finalizing its previously-disclosed settlement in principle with various states which filed similar civil suits related to Exjade. Today's agreement, and the anticipated agreements with the states, resolves all related federal and state civil claims on these matters, including the litigation brought by the qui tam relator David Kester, which concerned Exjade and Myfortic, as well as TOBI, Tasigna and Gleevec. In line with the Company's prior disclosure on October 27, 2015, the final settlement agreement announced includes total payments of $390 million to the federal government and state Medicaid programs to resolve allegations related to conduct dating to 2004. NPC has agreed to certain obligations relating to the company's interactions with specialty pharmacies in an addendum to its existing corporate integrity agreement (CIA) with the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services, which will be extended for five years. The company believes this resolution and the new CIA obligations will provide greater clarity as continue to work with independent specialty pharmacies in support of patient care. NPC will implement the agreed upon controls to ensure appropriate support for patients, and compliance with all Federal Healthcare program requirements related to its interactions with specialty pharmacies. These controls include enhancing policies and procedures at NPC for specialty pharmacy service arrangements and contracts, training for NPC associates, as well as strengthened monitoring and tracking processes to ensure that services are provided in a compliant manner. NPC will provide its contracted specialty pharmacies with a clear understanding of the Novartis Code of Conduct and training on the policies that guide activities to help ensure compliance with Federal Healthcare program requirements. The Company will also provide a comprehensive annual report to the government on continued compliance with these and other CIA obligations.
Novartis Pharmaceuticals Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 02:00 PM
Oct 6 15
Novartis Pharmaceuticals Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 02:00 PM. Venue: The Phoenician Hotel, Scottsdale, Arizona, United States. Speakers: Christi Shaw, President, US Country Head and President of Novartis Corporation.
Novartis Pharmaceuticals Corporation Presents at FT Latin America Healthcare and Life Sciences Summit 2015, Sep-29-2015 12:10 PM
Sep 28 15
Novartis Pharmaceuticals Corporation Presents at FT Latin America Healthcare and Life Sciences Summit 2015, Sep-29-2015 12:10 PM. Venue: Miami, Florida, United States. Speakers: Fabrice Chouraqui, Head, Region Latin America & Canada.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|